CytomX Therapeutics Inc (CTMX)
NASDAQ:CTMX
Total Valuation
CytomX Therapeutics has a market cap or net worth of $985.77M. The enterprise value is $767.92M.
Market Cap$985.77M
Enterprise Value$767.92M
Share Statistics
CytomX Therapeutics has 216,177,300 shares outstanding. The number of shares has decreased by -2.65% in one year.
Shares Outstanding216,177,300
Owned by Insiders1.36%
Owned by Institutions44.13%
Financial Efficiency
CytomX Therapeutics’s return on equity (ROE) is -0.18 and return on invested capital (ROIC) is -17.92%.
Return on Equity (ROE)-0.18
Return on Assets (ROA)-0.11
Return on Invested Capital (ROIC)-17.92%
Return on Capital Employed (ROCE)-0.19
Revenue Per Employee640.34K
Profits Per Employee-171.18K
Employee Count119
Asset Turnover0.50
Inventory Turnover0.00
Valuation Ratios
The current PE Ratio of CytomX Therapeutics is ―. CytomX Therapeutics’s PEG ratio is 0.24.
PE Ratio―
PS Ratio7.71
PB Ratio5.93
Price to Fair Value5.93
Price to FCF-7.75
Price to Operating Cash Flow-10.27
PEG Ratio0.24
Income Statement
In the last 12 months, CytomX Therapeutics had revenue of 76.20M and earned -17.37M in profits. Earnings per share was -0.15.
Revenue76.20M
Gross Profit76.20M
Operating Income-19.56M
Pretax Income-17.13M
Net Income-17.37M
EBITDA-18.19M
Earnings Per Share (EPS)-0.15
Cash Flow
In the last 12 months, operating cash flow was -75.59M and capital expenditures -220.00K, giving a free cash flow of -75.81M billion.
Operating Cash Flow-75.59M
Free Cash Flow-75.81M
Free Cash Flow per Share-0.35
Dividends & Yields
CytomX Therapeutics pays an annual dividend of ―, resulting in a dividend yield of ―
Dividend Per Share―
Dividend Yield―
Payout RatioN/A
Free Cash Flow Yield―
Earnings Yield―
Stock Price Statistics
Beta2.68
52-Week Price Change958.00%
50-Day Moving Average5.21
200-Day Moving Average3.63
Relative Strength Index (RSI)46.66
Average Volume (3m)9.87M
Important Dates
CytomX Therapeutics upcoming earnings date is Apr 30, 2026, After Close (Confirmed).
Last Earnings DateMar 16, 2026
Next Earnings DateApr 30, 2026
Ex-Dividend Date―
Financial Position
CytomX Therapeutics as a current ratio of 3.09, with Debt / Equity ratio of 4.28%
Current Ratio3.09
Quick Ratio3.09
Debt to Market Cap<0.01
Net Debt to EBITDA0.46
Interest Coverage Ratio0.00
Taxes
In the past 12 months, CytomX Therapeutics has paid 238.00K in taxes.
Income Tax238.00K
Effective Tax Rate-0.01
Enterprise Valuation
CytomX Therapeutics EV to EBITDA ratio is -31.84, with an EV/FCF ratio of -7.64.
EV to Sales7.60
EV to EBITDA-31.84
EV to Free Cash Flow-7.64
EV to Operating Cash Flow-7.66
Balance Sheet
CytomX Therapeutics has $137.05M in cash and marketable securities with $4.24M in debt, giving a net cash position of $132.81M billion.
Cash & Marketable Securities$137.05M
Total Debt$4.24M
Net Cash$132.81M
Net Cash Per Share$0.61
Tangible Book Value Per Share$0.71
Margins
Gross margin is 99.33%, with operating margin of -25.67%, and net profit margin of -22.79%.
Gross Margin99.33%
Operating Margin-25.67%
Pretax Margin-22.48%
Net Profit Margin-22.79%
EBITDA Margin-23.87%
EBIT Margin-25.67%
Analyst Forecast
The average price target for CytomX Therapeutics is $13.67, which is 11.43% higher than the current price. The consensus rating is Strong Buy
Price Target$13.67
Price Target Upside199.78% Upside
Analyst ConsensusStrong Buy
Analyst Count9
Revenue Growth Forecast-10.26%
EPS Growth Forecast144.62%